Pituitary Macroadenoma Clinical Trial
Official title:
A Single-center, Prospective, Randomized Controlled Trial Investigating the Utility if Intraoperative MRI in Transphenoidal Pituitary Surgery Off Macroadenomas.
Verified date | August 2023 |
Source | Dartmouth-Hitchcock Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators are studying the utility of intra-operative magnetic resonance imaging (iMRI) during transsphenoidal pituitary surgery for large macroadenomas by randomizing patients to either an intra-operative MRI after resection, or no intra-operative MRI. The investigators will then count the number of gross total resection in each group of patients and also the complications related to surgery.
Status | Terminated |
Enrollment | 10 |
Est. completion date | July 1, 2023 |
Est. primary completion date | July 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: - Adults 18-90 - Capable of giving informed consent - Elect for transsphenoidal surgery - Has pre-operative MRI demonstrating pituitary tumor that is: 1. deemed resectable using a transsphenoidal approach and 2. has a maximal diameter equal to or greater than 15 mm. - No contraindications for MRI. Exclusion Criteria: - Children (age < 18) - Not able to give consent - No pituitary tumor visible on MRI or an adenoma measuring less than 15mm in maximal dimension. - Unable to tolerate MRI |
Country | Name | City | State |
---|---|---|---|
United States | Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire |
Lead Sponsor | Collaborator |
---|---|
Dartmouth-Hitchcock Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of gross total or maximal resection | Determine whether use of iMRI in transsphenoidal pituitary surgery for pituitary macroadenomas significantly increases the rate of maximal resection | 24 hours after surgery | |
Secondary | Operative time | Length of operation | intraoperative | |
Secondary | Frequency of post-operative CSF leak | Frequency of post-operative Cerebrospinal Fluid (CSF) leak | 30 days post surgery | |
Secondary | Rate of Readmission | Frequency of readmission | 30 days post surgery | |
Secondary | Length of anesthesia time | Length of time participant is under anesthesia | intraoperative | |
Secondary | Rate of post-operative endocrinopathies | Rate of post-operative endocrinopathies | 30 days post surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01444209 -
Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas
|
Phase 2 | |
Completed |
NCT04212793 -
Detection of PitNET Tissue During TSS Using Bevacizumab-800CW
|
Phase 1 |